Global Opioid Induced Constipation Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Opioid Induced Constipation Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
Opioid Induced Constipation Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Opioid Induced Constipation Drugs market is projected to reach US$ 3490.4 million in 2034, increasing from US$ 2531 million in 2022, with the CAGR of 4.6% during the period of 2024 to 2034. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.
North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Opioid Induced Constipation Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Ironwood Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Pfizer
Progenics Pharmaceuticals Inc
Shionogi & Co., Ltd
Allergan Plc
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma AG
Mundipharma International Limited
Ono Pharmaceutical Co., Ltd
Takeda Pharmaceutical Company Limited
Theravance Biopharma Inc
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Segment by Type
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Others
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Opioid Induced Constipation Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Opioid Induced Constipation Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Opioid Induced Constipation Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Opioid Induced Constipation Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Opioid Induced Constipation Drugs introduction, etc. Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Opioid Induced Constipation Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Opioid Induced Constipation Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Opioid Induced Constipation Drugs market is projected to reach US$ 3490.4 million in 2034, increasing from US$ 2531 million in 2022, with the CAGR of 4.6% during the period of 2024 to 2034. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.
North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Opioid Induced Constipation Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Ironwood Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Pfizer
Progenics Pharmaceuticals Inc
Shionogi & Co., Ltd
Allergan Plc
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma AG
Mundipharma International Limited
Ono Pharmaceutical Co., Ltd
Takeda Pharmaceutical Company Limited
Theravance Biopharma Inc
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Segment by Type
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Opioid Induced Constipation Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Opioid Induced Constipation Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Opioid Induced Constipation Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Opioid Induced Constipation Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Opioid Induced Constipation Drugs introduction, etc. Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Opioid Induced Constipation Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices